Article Text

A8.06 Microrna-125b expression in PBMCS is inversely associated with disease activity in patients with early rheumatoid arthritis
  1. V Hruskova1,2,
  2. R Jandova1,
  3. L Vernerova1,
  4. H Mann1,
  5. K Prajzlerova1,
  6. M Filkova1,
  7. K Pavelka1,
  8. J Vencovsky1,
  9. L Senolt1
  1. 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University in Prague, Czech Republic
  2. 2Faculty of Science Charles University in Prague, Czech Republic


Background and objectives MicroRNAs (miRNAs) are small RNAs that regulate gene expression by targeting mRNA. It was proved that some miRNAs are significantly deregulated in rheumatoid arthritis (RA). MicroRNA-125b negatively regulates expression of TNF-α, which plays a crucial role in RA pathogenesis. The aim of this study was to evaluate the expression of miRNA-125b in peripheral blood mononuclear cells (PBMCs) and its association with disease activity and treatment response in early RA patients.

Materials and methods A total of 58 (42 females; mean age 54.3 ± 16.4 years) early RA patients and 54 (41 females; mean age 50.9 ± 15.11 years) healthy controls (HC) were studied. Total RNA was isolated from PBMCs collected from patients before and after three months of glucocorticoid/disease modifying antirheumatic drugs treatment and from HC. The expression of miRNA-125b was determined by quantitative PCR. RNU44 was used for normalisation. Disease activity was defined using 28-Joint Count Disease activity Score (DAS28-ESR). The expression of miRNA-125b was studied in order to predict treatment response characterised by achieving remission or alternatively low disease activity (DAS28 < 3.2).

Results The expression of miRNA-125b was significantly lower in early RA patients compared to HC (p = 0.001) and increased after three months of therapy (p = 0.006), mainly in responders (p = 0.019). At baseline, miRNA-125b expression negatively correlated with DAS28 (r = -0.462; p = 0.0003). In addition, baseline miRNA-125b expression predicted treatment response after three months which was performed by ROC curve analysis (AUC: 0.663 [95% CI 0.520 to 0.805]; p = 0.048).

Conclusion Monitoring of miRNA-125b could be used as a  biomarker of disease activity and treatment response in  early RA.

Acknowledgement IGA project No NT 14498; GAUK-367615.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.